Presenting author
Anna Elgart
2 presentations
PS02-2243. Injection site reactions and local tolerability with subcutaneous long-acting injectable olanzapine (TV-44749) in schizophrenia: phase 3 SOLARIS trial results
PS02-2244. Long-term quality of life of adults with schizophrenia treated with subcutaneous long-acting injectable olanzapine (TV-44749): SOLARIS phase 3 results